Tiziana Life Sciences Ltd (NASDAQ:TLSA - Get Free Report) saw a large drop in short interest in the month of February. As of February 28th, there was short interest totalling 567,600 shares, a drop of 39.2% from the February 13th total of 934,300 shares. Currently, 0.8% of the shares of the company are short sold. Based on an average trading volume of 955,300 shares, the days-to-cover ratio is currently 0.6 days.
Tiziana Life Sciences Trading Down 8.9 %
Shares of TLSA stock traded down $0.14 during midday trading on Wednesday, hitting $1.39. The company had a trading volume of 551,618 shares, compared to its average volume of 437,386. The company's 50 day simple moving average is $0.95 and its 200 day simple moving average is $0.93. Tiziana Life Sciences has a 52-week low of $0.41 and a 52-week high of $1.91.
Hedge Funds Weigh In On Tiziana Life Sciences
Several institutional investors have recently bought and sold shares of the company. Bison Wealth LLC purchased a new stake in shares of Tiziana Life Sciences in the fourth quarter valued at about $30,000. Geode Capital Management LLC increased its position in Tiziana Life Sciences by 12.4% during the 4th quarter. Geode Capital Management LLC now owns 245,722 shares of the company's stock worth $171,000 after purchasing an additional 27,041 shares during the period. Zhang Financial LLC increased its position in Tiziana Life Sciences by 34.3% during the 4th quarter. Zhang Financial LLC now owns 93,187 shares of the company's stock worth $65,000 after purchasing an additional 23,800 shares during the period. Finally, Sanctuary Advisors LLC purchased a new position in shares of Tiziana Life Sciences during the 3rd quarter worth approximately $864,000.
About Tiziana Life Sciences
(
Get Free Report)
Tiziana Life Sciences Ltd, a biotechnology company, focuses on the discovery and development of molecules to treat human diseases in oncology and immunology. The company's lead product candidate in immunology is Foralumab (TZLS-401), a human anti-CD3 monoclonal antibody (mAb) for the treatment of Crohn's, graft versus host, ulcerative colitis, multiple sclerosis, type-1 diabetes, inflammatory bowel, psoriasis, and rheumatoid arthritis diseases.
Further Reading
Before you consider Tiziana Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Tiziana Life Sciences wasn't on the list.
While Tiziana Life Sciences currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
